共 40 条
[1]
Talley NJ(1995)Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization Am J Epidemiol 142 76-83
[2]
Zinsmeister AR(2001)The irritable bowel syndrome N Engl J Med 344 1846-1850
[3]
Melton LJ(2000)Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population Br J Surg 87 1658-1663
[4]
Horwitz BJ(2003)Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome Aliment Pharmacol Ther 17 997-1005
[5]
Fisher RS(2002)Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms Am J Gastroenterol 97 1176-1181
[6]
Kennedy TM(2003)An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome Gut 52 671-676
[7]
Jones RH(2001)Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment Pharmacol Ther 15 1655-1666
[8]
Hasler WL(2002)A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation Aliment Pharmacol Ther 16 1877-1888
[9]
Schoenfeld P(1995)Use of insurance claims in epidemiologic research: Identification of peptic ulcers, GI bleeding, pancreatitis, hepatitis and renal disease Pharmacoepidemiol Drug Saf 4 239-248
[10]
Fidelholtz J(1993)Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population Med Care 31 498-507